knowledge -WSS

knowledge

author：knowledge 2025-10-01 23:57:12 - browse：9773

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Sana to lay off nearly a third of staff, de

hotspot

WSS

Histogen: Failed biotech offers rare public look inside

FDA panel signals lack of confidence in Amgen cancer drug data

A $475,000 price tag for a new cancer drug: crazy or meh?

Medicare drug price negotiation’s day in court

When women are denied an abortion, their children fare worse than peers

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Wikipedia

knowledge

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Cybersecurity threat forces Lurie Children's to take systems offline

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Apple is now the first public company to be valued at $3 trillion

Bristol 'take

State Dept. review finds Biden bears some blame for Afghanistan failures

Phenylephrine and the overlooked value of the placebo effect

After affirmative action ruling, medical educators look to 'holistic review'

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

ARCH Venture Partners is raising $3 billion for a life sciences fund

Medicare drug price negotiation’s day in court

The real point of Kenneth Smith’s execution by nitrogen gas

Chan Zuckerberg Biohub Chicago to focus on inflammation

Sana to lay off nearly a third of staff, de

focus

Wikipedia

hotspot

Wikipedia